Clinical trials: Chronic Renal Failure
Chronic Kidney Disease and Hypertension
A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.
International, Multicenter and Double-Blind study. The purpose is to measure the effect of baxdrostat in combination with dapagliflozin compared with baxdrostat/placebo on albuminuria, as well as safety, in participants with…
- Trial name
- BaxDuo-Baltic (NCT07222917)
- Testing
- Baxdrostat/dapagliflozin
- Where
- 55 sites in United States, Argentina and 7 more
- Volunteers
- 222 people
- Sponsor
- AstraZeneca
Chronic Kidney Disease
A Study to Evaluate the Safety and Pharmacokinetics With MEDI8367 Administered in Healthy Subjects, and in Subjects With Chronic Kidney Disease
This Phase I First in Human (FIH) study is being conducted to determine the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity profile of MEDI8367 across the dose range.
- Trial name
- NCT04365218
- Testing
- MEDI8367
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Participants
A Study to Investigate the Safety, Tolerability and Pharmacodynamics of AZD4144 in Participants With Obesity
The aim of this study is to evaluate the safety and tolerability, and pharmacodynamics (PD) of AZD4144 administered as repeated daily oral dosing.
- Trial name
- NCT06942923
- Testing
- AZD4144
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Heart Failure
Evaluation of Patiromer Titration in Heart Failure Patients With Chronic Kidney Disease
The purpose of this study was to evaluate the feasibility of individualized titration of patiromer according to serum potassium.
- Trial name
- NCT01130597
- Testing
- patiromer, spironolactone
- Where
- 13 sites in Georgia, Slovenia
- Volunteers
- 63 people
- Sponsor
- Relypsa, Inc.
End Stage Renal Disease, Hyperparathyroidism, Secondary
Mineral and Bone Disorders Outcomes in Stage 5D of Chronic Kidney Disease
The MBD-5D is a prospective observational study with a case-cohort and a cohort design. Eligible patients are receiving hemodialysis and have secondary hyperparathyroidism.
- Trial name
- MBD-5D (NCT00995163)
- Where
- Japan
- Volunteers
- 8,020 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Chronic Kidney Disease, Type 2 Diabetes Mellitus
An Observational Study, Called FINEXPLORER, to Learn More About How Well Finerenone Works in Adults in Spain With Chronic Kidney Disease (CKD) Linked to Type 2 Diabetes, by Looking at Changes in a CKD Risk Score
This is a prospective observational study in which data from people with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) who will be receiving finerenone are collected and analyzed.
- Trial name
- FINEXPLORER (NCT07554469)
- Testing
- Finerenone (Kerendia, BAY94-8862)
- Where
- Spain
- Volunteers
- 500 people
- Sponsor
- Bayer
Anemia, End Stage Renal Disease
Artificial Intelligence for Optimal Anemia Management in End-stage Renal Disease: The Anemia Control Model (ACM) Trial
Fresenius Medical Care has developed a computer software programme called the Anaemia Control Management (ACM) software to assist in the anaemia management of patients with chronic kidney disease (CKD) undergoing hemodialysis.
- Trial name
- ANEMEX (NCT03214627)
- Testing
- Anemia Control Model (ACM), IV iron, Erythropoiesis-Stimulating Agent (ESA)
- Where
- United Kingdom
- Volunteers
- 88 people
- Sponsor
- Vifor Fresenius Medical Care Renal Pharma
Kidney Disease, Chronic Kidney Disease
Study to Assess Darbepoetin Alfa in Subjects With Chronic Kidney Disease
The purpose of this study is to determine whether darbepoetin alfa manufactured by the current "roller bottle" technology and darbepoetin alfa manufactured by a serum free process have a comparable safety profile.
- Trial name
- NCT00093977
- Testing
- darbepoetin alfa SF
- Volunteers
- 1,100 people
- Sponsor
- Amgen
Kidney Failure, Chronic
A Phase II Study to Evaluate the Efficacy of IdeS to Desensitize Transplant Patients With a Positive Crossmatch Test
The purpose of this study is to evaluate the effectiveness of the study drug IdeS in patients who are on the waiting list for kidney transplant and have previously undergone desensitization unsuccessfully or in whom effective…
- Trial name
- Highdes (NCT02790437)
- Testing
- IdeS, Kidney transplantation
- Where
- 5 sites in United States, France and 1 more
- Volunteers
- 19 people
- Sponsor
- Hansa Biopharma AB
Chronic Kidney Disease, Anemia, Iron-Deficiency
A Study of Iron Oligosaccharide in Chronic Kidney Disease Patients
The purpose of this study is to determine the safety profile of iron oligosaccharide in patients with chronic kidney disease with a need for parenteral iron.
- Trial name
- NCT00536666
- Testing
- Iron oligosaccharide
- Where
- Denmark
- Volunteers
- 182 people
- Sponsor
- Pharmacosmos A/S
Anemia
Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease Patients
The study will evaluate the safety and efficacy of a new intravenously administered iron drug to treat anemia in patients with chronic kidney disease who are not on dialysis.
- Trial name
- NCT00255437
- Testing
- ferumoxytol or oral iron
- Where
- 13 sites in United States
- Volunteers
- 304 people
- Sponsor
- AMAG Pharmaceuticals, Inc.
Type 2 Diabetes Mellitus, Chronic Kidney Disease
A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease
To assess the safety and efficacy of up to two REACT injections given 6 months (+4 weeks) apart and delivered into the biopsied kidney using a percutaneous approach in participants with Type 2 Diabetes Mellitus (T2DM) and Chronic…
- Trial name
- NCT02836574
- Testing
- Renal Autologous Cell Therapy (REACT), Renal Biopsy
- Where
- 16 sites in United States
- Volunteers
- 83 people
- Sponsor
- Prokidney
Iron Deficiency Anaemia, Iron Deficiency Anemia
Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease
Evaluation of safety and efficacy of iron isomaltoside/ferric derisomaltose compared with iron sucrose, in subjects with both non-dialysis-dependent chronic kidney disease (NDD-CKD) and iron deficiency anaemia (IDA).
- Conditions
- Iron Deficiency Anaemia, Iron Deficiency Anemia, Chronic Kidney Disease
- Trial name
- NCT02940860
- Testing
- Iron isomaltoside/ferric derisomaltose, Iron sucrose
- Where
- 141 sites in United States
- Volunteers
- 1,538 people
- Sponsor
- Pharmacosmos A/S
Calciphylaxis
SEAPORT 1: Study of INZ-701 in Adults With Hemodialysis-Dependent End-Stage Kidney Disease
This Phase 1, open-label, multicenter study evaluated the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of INZ-701 in adults with hemodialysis-dependent end-stage kidney disease (ESKD) and low plasma inorganic…
- Trial name
- SEAPORT 1 (NCT06283589)
- Testing
- INZ-701
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Inozyme Pharma
Chronic Kidney Disease, Renal Dialysis
A Phase 3 Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Peritoneal Dialysis
This is a multi-center, open-labeled, non-comparative study to examine the safety and efficacy of ASP1585 in chronic kidney disease and hyperphosphatemia patients on peritoneal dialysis.
- Conditions
- Chronic Kidney Disease, Renal Dialysis, Renal Insufficiency
- Trial name
- NCT01017276
- Testing
- ASP1585
- Where
- 3 sites in Japan
- Volunteers
- 35 people
- Sponsor
- Astellas Pharma Inc
Anemia
An Observational Study of Patients' Perception of Treatment With Erythropoiesis-Stimulating Agents in Patients With Chronic Kidney Disease Not on Dialysis (PERCEPOLIS)
This observational study will evaluate patients' perception of treatment with erythropoiesis-stimulating agents in patients with chronic kidney disease not on dialysis.
- Trial name
- NCT02042833
- Where
- 109 sites in France
- Volunteers
- 815 people
- Sponsor
- Hoffmann-La Roche
Chronic Kidney Disease
A Study to Learn About How a New Nurandociguat Tablet is Absorbed and Processed in the Body Compared to an Old Tablet and How Food Affects the Way the New Tablet is Absorbed and Processed in the Body
Researchers conduct this clinical study to learn more about a new tablet of a medicine called nurandociguat. Nurandociguat is being developed as a possible treatment for people with chronic kidney disease (CKD) which is a…
- Trial name
- NCT07722585
- Testing
- Nurandociguat (BAY3283142) old tablet - SD, Nurandociguat (BAY3283142) new tablet - SD, Nurandociguat (BAY3283142) old tablet
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bayer
Renal Insufficiency, Chronic
Short-term Metabolic Effects of Ketosteril® Supplemented Low Protein Diet in Pre-dialysis Chronic Kidney Disease (CKD) Patients
Supplementation of ketoanalogues of essential amino acids improves the protein quality of protein restricted diets without burdening the kidneys.
- Trial name
- CKD (NCT03077048)
- Testing
- Ketosteril®
- Where
- Czechia
- Volunteers
- 23 people
- Sponsor
- Fresenius Kabi
Kidney Disease
Aranesp® Monthly Preference Study - 2
The purpose of this study was to evaluate subject preference for Aranesp® administered once monthly (i.e., every 4 weeks (Q4W)) or Procrit® administered once weekly (QW).
- Trial name
- NCT00117078
- Testing
- Aranesp®
- Sponsor
- Amgen
Chronic Renal Failure
Study of Clinical Non-inferiority of Actparin® (Laboratorio Bergamo) Compared to Heparin Sodium (APP Pharmaceuticals), in Patients With Chronic Renal Failure
The purpose of this study is to investigate clinical non-inferiority, pharmacodynamic effect and safety of Actparin® (heparin sodium - Laboratório Químico Farmacêutico Bergamo Ltd.) compared to Heparin Sodium (APP…
- Trial name
- NCT01346215
- Testing
- heparin sodium
- Where
- Brazil
- Volunteers
- 132 people
- Sponsor
- Laboratório Químico Farmacêutico Bergamo Ltda.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.